Cite

    Borlenghi, E. et al. (2020). Postremission therapy with repeated courses of high‐dose cytarabine, idarubicin, and limited autologous stem cell support achieves a very good long‐term outcome in European leukemia net favorable and intermediate‐risk acute myeloid leukemia. Hematological oncology. 38 (5), pp. 754-762. [Online].